SGMOQ insider buying and SEC filings, explained
Sangamo Therapeutics, Inc. · CIK 1001233
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$107K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Apr 22, 2026 | Sale | Gregory D Davis (Head of Research & Technology) sold 69,827 shares at about $0.2500 ($17K). Holdings down 38% to 115,284 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 23, 2026 |
| Apr 21, 2026 | Sale | Nathalie Dubois-Stringfellow (SVP-Chief Development Officer) sold 345,942 shares at about $0.2600 ($90K). Holdings down 51% to 332,769 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 23, 2026 |
27 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SGMOQ in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.